ViewRay Revenue and Competitors
Estimated Revenue & Valuation
- ViewRay's estimated annual revenue is currently $167M per year.
- ViewRay received $172.5M in venture funding in August 2018.
- ViewRay's estimated revenue per employee is $742,222
- ViewRay's total funding is $752.8M.
- ViewRay has 225 Employees.
- ViewRay grew their employee count by -4% last year.
What Is ViewRay?
MRI-GUIDED ADAPTIVE RADIOTHERAPY ViewRay®, Inc. (NASDAQ:VRAY), designs, manufactures, and markets the MRIdian® radiation therapy system to address the key limitations of existing external-beam radiation therapy technologies. MRIdian employs MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription as needed. ViewRay believes this combination of enhanced visualization, on-line adapting and accurate dose recording will significantly improve the safety and efficacy of radiation therapy, leading to better outcomes for patients. At ViewRay, our vision is clear. We're dedicated to giving doctors new and better ways to treat cancer with radiation therapy. We're an entrepreneurial company with big ambitions, unlimited potential and a passion for improving the lives of patients with cancer. We're always on the lookout for talented people who share our commitment and values. Contact us if you're enthusiastic about working with a close-knit team and motivated by the prospect of making a difference.keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals
Number of Employees
Employee Growth %
How Healthy Is ViewRay's Balance Sheet? We can see from the most recent balance sheet that ViewRay had liabilities of US$76.2m falling due...
ViewRay, Inc. (NASDAQ:VRAY Get Rating) has been assigned a consensus recommendation of Hold from the seven ratings firms that are...
(Nasdaq: VRAY) announced today details relating to the release of its first quarter 2022 financial results. ViewRay will hold a conference call...
ViewRay Announces 510(k) Pending Status of the Newest Generation of MRIdian Innovations New suite of workflow and clinical features to be highlighted at upcoming ASTRO 2021 conference CLEVELAND, OH, September 29, 2021-ViewRay, Inc. (NASDAQ: VRAY) today announced that the company has received a ...
CLEVELAND, Aug. 24, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the clinical team at Amsterdam University Medical Centers (Amsterdam UMC) has started offering "same-day ablative treatment" using MRIdian SMART (stereotactic MR-guided adaptive radiotherapy) for patient ...
|2009-04-14||$25.0M||B||OrbiMed Advisors, Fidelity Biosciences||Article|
|2013-12-18||$30.0M||Undisclosed||Cowealth Medical Holding Co Ltd||Article|
|2016-08-22||$13.8M||Undisclosed||OrbiMed Advisors, LLC||Article|
|2017-01-19||$Undisclosed||Undisclosed||Puissance Capital Management||Article|